Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Retained Earnings: 2016-2025

Historic Retained Earnings for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to -$1.7 billion.

  • Akebia Therapeutics' Retained Earnings fell 0.96% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 0.96%. This contributed to the annual value of -$1.7 billion for FY2024, which is 4.31% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Retained Earnings is -$1.7 billion, which was up 0.03% from -$1.7 billion recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Retained Earnings registered a high of -$1.2 billion during Q1 2021, and its lowest value of -$1.7 billion during Q4 2024.
  • Moreover, its 3-year median value for Retained Earnings was -$1.6 billion (2024), whereas its average is -$1.6 billion.
  • Data for Akebia Therapeutics' Retained Earnings shows a maximum YoY slumped of 45.89% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Retained Earnings stood at -$1.5 billion in 2021, then dropped by 6.44% to -$1.6 billion in 2022, then declined by 3.33% to -$1.6 billion in 2023, then fell by 4.31% to -$1.7 billion in 2024, then dropped by 0.96% to -$1.7 billion in 2025.
  • Its Retained Earnings was -$1.7 billion in Q3 2025, compared to -$1.7 billion in Q2 2025 and -$1.7 billion in Q1 2025.